CN102438449B - 抗癌药物及将其用于治疗恶性黑色素瘤及其它癌症 - Google Patents

抗癌药物及将其用于治疗恶性黑色素瘤及其它癌症 Download PDF

Info

Publication number
CN102438449B
CN102438449B CN201080016304.7A CN201080016304A CN102438449B CN 102438449 B CN102438449 B CN 102438449B CN 201080016304 A CN201080016304 A CN 201080016304A CN 102438449 B CN102438449 B CN 102438449B
Authority
CN
China
Prior art keywords
pharmaceutical composition
compound
cancer
pharmaceutically acceptable
dimethylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080016304.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN102438449A (zh
Inventor
G·R·古卡拉吉
S·卡斯娜
R·R·古卡拉吉
V·K·R·R·古卡拉吉
V·索门帕利
T·吉拉考提
K·布湖帕瑟拉吉
K·森古卜他
V·K·R·阿鲁瑞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laila Nutraceuticals
Original Assignee
Laila Nutraceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laila Nutraceuticals filed Critical Laila Nutraceuticals
Publication of CN102438449A publication Critical patent/CN102438449A/zh
Application granted granted Critical
Publication of CN102438449B publication Critical patent/CN102438449B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/04—1,2,3-Triazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D517/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C07D517/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms in which the condensed system contains three hetero rings
    • C07D517/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201080016304.7A 2009-04-27 2010-04-26 抗癌药物及将其用于治疗恶性黑色素瘤及其它癌症 Expired - Fee Related CN102438449B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN959/CHE/2009 2009-04-27
IN959CH2009 2009-04-27
PCT/IN2010/000262 WO2010125575A1 (en) 2009-04-27 2010-04-26 Anti-cancer drugs, and uses relating for malignant melanoma and other cancers

Publications (2)

Publication Number Publication Date
CN102438449A CN102438449A (zh) 2012-05-02
CN102438449B true CN102438449B (zh) 2014-06-18

Family

ID=42992332

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080016304.7A Expired - Fee Related CN102438449B (zh) 2009-04-27 2010-04-26 抗癌药物及将其用于治疗恶性黑色素瘤及其它癌症

Country Status (11)

Country Link
US (1) US8143237B2 (OSRAM)
EP (1) EP2424351B1 (OSRAM)
JP (1) JP5571168B2 (OSRAM)
KR (1) KR20120006554A (OSRAM)
CN (1) CN102438449B (OSRAM)
AU (1) AU2010243213B2 (OSRAM)
BR (1) BRPI1006651A2 (OSRAM)
CA (1) CA2759519A1 (OSRAM)
IL (1) IL215789A0 (OSRAM)
NZ (1) NZ595602A (OSRAM)
WO (1) WO2010125575A1 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2640392B1 (en) * 2010-11-18 2015-01-07 Kasina Laila Innova Pharmaceuticals Private Ltd. Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
US9090633B2 (en) 2010-11-18 2015-07-28 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof
AU2011340063B2 (en) * 2010-12-09 2016-03-24 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof
WO2012176212A1 (en) 2011-06-20 2012-12-27 V.B. Medicare Pvt. Ltd. Carrier based nanogel formulation for skin targeting.
CN103906742A (zh) * 2011-09-28 2014-07-02 世宗大学校产学协力团 硒吩稠合芳族化合物和其制备方法
KR101418776B1 (ko) 2011-09-28 2014-07-14 사회복지법인 삼성생명공익재단 셀레노펜-접합 방향족 화합물, 및 이의 제조 방법
US8859781B2 (en) 2012-07-12 2014-10-14 Euclises Pharmaceuticals, Inc. No-releasing nonoate(nitrogen-bound)sulfonamide-linked-coxib anti-cancer agents
WO2014012000A2 (en) 2012-07-12 2014-01-16 Euclises Pharmaceuticals, Inc. No-releasing guanidine-coxib anti-cancer agents
WO2014018888A1 (en) 2012-07-26 2014-01-30 Confluence Life Sciences Inc. 4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds as tak1 inhibitors in disease treatment
US20150353542A1 (en) 2013-01-14 2015-12-10 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
AU2016209046A1 (en) 2015-01-23 2017-07-20 Aclaris Therapeutics, Inc. Heterocyclic ITK inhibitors for treating inflammation and cancer
CN108129475A (zh) * 2018-02-08 2018-06-08 中南大学湘雅三医院 一种生物光敏剂及其制备方法和应用
KR102648781B1 (ko) 2021-11-09 2024-03-19 국립공주대학교 산학협력단 항암 활성을 갖는 인데노피라졸론 유도체 화합물, 그의 제조방법 및 그의 용도
WO2025005748A1 (ko) * 2023-06-29 2025-01-02 (주)아이젠사이언스 신규 셀레노펜 유도체

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070197493A1 (en) * 1996-06-03 2007-08-23 Purdue Research Foundation Selenophene anti-tumor agents
WO2008016664A2 (en) * 2006-08-02 2008-02-07 University Of Massachusetts Lowell Compositions and methods for treating cancer with dacarbazine nanoemulsions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1021178B1 (en) * 1996-06-03 2003-08-27 Purdue Research Foundation Selenophene anti-tumor agents
BRPI0913485A2 (pt) * 2008-09-15 2016-06-07 Kasina Laila Innova Pharmaceuticals Private Ltd medicamentos anticâncer e usos relacionados para melanoma maligno metastático e outros cânceres.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070197493A1 (en) * 1996-06-03 2007-08-23 Purdue Research Foundation Selenophene anti-tumor agents
WO2008016664A2 (en) * 2006-08-02 2008-02-07 University Of Massachusetts Lowell Compositions and methods for treating cancer with dacarbazine nanoemulsions

Also Published As

Publication number Publication date
AU2010243213B2 (en) 2014-09-11
HK1166591A1 (en) 2012-11-02
KR20120006554A (ko) 2012-01-18
NZ595602A (en) 2013-05-31
US8143237B2 (en) 2012-03-27
EP2424351B1 (en) 2015-10-21
JP2012525329A (ja) 2012-10-22
JP5571168B2 (ja) 2014-08-13
EP2424351A1 (en) 2012-03-07
EP2424351A4 (en) 2013-04-03
AU2010243213A1 (en) 2011-10-27
CA2759519A1 (en) 2010-11-04
US20100272678A1 (en) 2010-10-28
BRPI1006651A2 (pt) 2015-08-25
WO2010125575A1 (en) 2010-11-04
CN102438449A (zh) 2012-05-02
IL215789A0 (en) 2012-01-31

Similar Documents

Publication Publication Date Title
CN102438449B (zh) 抗癌药物及将其用于治疗恶性黑色素瘤及其它癌症
CN102149703B (zh) 抗癌药物及将其用于治疗转移性恶性黑色素瘤及其他癌症
US7022850B2 (en) Bicyclicpyrimidones and their use to treat diseases
US9249106B2 (en) Substituted hydrazide compounds and use thereof
US20160009729A1 (en) Nitrogen-containing heterocyclic ring substituted dihydroartemisinin derivatives and use thereof
JP2017501204A (ja) １，２ナフトキノン誘導体及びその製造方法
CN104530038A (zh) 酰胺咪唑类衍生物及其用途
US20040097539A1 (en) Hsp inductor
US11370766B2 (en) Sulfonyl amidine as indoleamine-2,3-dioxygenase inhibitor, and preparation method therefor and use thereof
CN102659800B (zh) 一类低氧激活抗肿瘤化合物及其用途
HK1166591B (en) Anti-cancer drugs, and uses relating for malignant melanoma and other cancers
CN103906751A (zh) 作为晚期SV40因子（LSF）抑制剂用于治疗癌症的[1,3]二氧杂环戊烯并[4,5-g]喹啉-6(5H)-硫酮和[1,3]二氧杂环戊烯并[4,5-g][1,2,4]三唑并[1,5-a]喹啉衍生物
CN111170962B (zh) 4-(苯并硒唑-2-基)芳胺类化合物治疗肠癌的用途
US20160102066A1 (en) Benzothiazole derivative and anti-tumor use thereof
CN116685324A (zh) 用于预防或治疗与ron突变相关的胰腺癌的药物组合物及其使用方法
CN104250257B (zh) 3,4‑二氢‑1H‑苯并[c][1,2]噁硼酸类化合物或其可药用盐及其制备方法和用途
CN106117176B (zh) 二氢双苯并恶庚衍生物及其组合物与应用
WO2024174949A1 (zh) 作为cdk7激酶抑制剂的杂芳环化合物及其制备和应用
CN118436643A (zh) Zak抑制剂在靶向肿瘤中的治疗策略及其应用
CN115260194A (zh) 新型egfr降解剂
CN103570721A (zh) 三唑并吡嗪（酮）以及异噁唑并哌啶酮类化合物
HK1154863A (en) Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers
EP3116882A2 (en) Compounds for eradicating or inhibiting proliferation of cancer stem cells

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1166591

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1166591

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140618

Termination date: 20170426